v3.25.2
COMMITMENTS AND CONTINGENCIES (Fair Value Contingent Consideration) (Details) - Contingent Consideration Liability - Level 3 - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, beginning of period $ 69,657 $ 87,312
Payment (23,075) (12,400)
Change in fair value of contingent consideration liabilities (203) 2,341
Balance, end of period 46,379 77,253
Short-Term - Accrued expenses and other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 21,279 27,444
Long-Term - Other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 25,100 49,809
Arkis    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, beginning of period 12,968 15,755
Payment (5,000)  
Change in fair value of contingent consideration liabilities (627) (934)
Balance, end of period 7,341 14,821
Arkis | Short-Term - Accrued expenses and other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 3,579 8,244
Arkis | Long-Term - Other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 3,762 6,577
Derma Sciences    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, beginning of period 2,686 2,557
Payment 0  
Change in fair value of contingent consideration liabilities (1,451) 75
Balance, end of period 1,235 2,632
Derma Sciences | Short-Term - Accrued expenses and other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 0 0
Derma Sciences | Long-Term - Other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 1,235 2,632
ACell    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, beginning of period 3 300
Payment 0  
Change in fair value of contingent consideration liabilities 0 0
Balance, end of period 3 300
ACell | Short-Term - Accrued expenses and other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 0 0
ACell | Long-Term - Other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 3 300
Surgical Innovation Associates, Inc.    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, beginning of period 54,000 68,700
Payment (18,075) (12,400)
Change in fair value of contingent consideration liabilities 1,875 3,200
Balance, end of period 37,800 59,500
Surgical Innovation Associates, Inc. | Short-Term - Accrued expenses and other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 17,700 19,200
Surgical Innovation Associates, Inc. | Long-Term - Other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period $ 20,100 $ 40,300